侵權投訴
訂閱
糾錯
加入自媒體

吉利德對瑞德西韋專利紛爭表態:患者第一,不希望卷入專利紛爭

2020-02-06 17:23
楓中漫步人
關注

2月5日晚,吉利德CEO Daniel O’Day在youtube上發表了一封公開郵件中表示,吉利德已與中國衛生部門達成了協議,將會支持對新型冠狀病毒感染者開展兩項臨床試驗,以確定瑞德西韋作為冠狀病毒潛在治療手段的安全性和有效性。根據最新的消息顯示,這次在武漢進行的臨床實驗有兩項,一是研究評估瑞德西韋用于未表現出顯著臨床癥狀患者的治療效果,也就是輕、重癥患者。另一項則是評估其用于重癥確診病患的療效。臨床試驗牽頭方中日友好醫院方面也進一步披露了細節:這次的臨床試驗將一共入組患者761例,其中輕、中癥患者308例,重癥患者453例。

針對近期網絡上熱議的關于瑞德西韋的專利紛爭,吉利德CEO Daniel O’Day在公開郵件表示,首先應該堅持患者第一,希望能夠推動更多的臨床項目確保真正對患者有幫助;其次,吉利德公司也希望推動量產,盡可能多地提供給全球患者。最后,公司的核心關注在于病人,不希望卷入專利糾紛

下面附上吉利德CEO Daniel O’Day在媒體上公開的郵件原文:

It’s a very relevant question. And obviously it just came out overnight, and like everything with regard to Remdesivir, ah, you know we are moving as quickly as we can. I think my message to you and everybody is that has no impact on what we are going to do with global health.

I just want to be tremendously clear here that our responsibility is the patients. And our responsibility is number one: pursue the right clinical programs to determine whether or not this medicine has impact with patients or not, and it’ll be driven by the science, by the clinical evidence.

And at the same time, ramping our production up, in the event that it does, we can get this medicine to as many patients around the globe as needed. Patent is not at the forefront of our minds.

I will say, ‘cause I checked with our patent colleagues, that as we would with any medicine at Gilead, we have patents on Remdesivir, not only for the compound, but also for all of its use including coronavirus in regions around the world.

But we will not get into a patent dispute, we will find a way to help patients, and of course, we will protect our intellectual property as a separate step of the process. But patients first.

聲明: 本文由入駐維科號的作者撰寫,觀點僅代表作者本人,不代表OFweek立場。如有侵權或其他問題,請聯系舉報。

發表評論

0條評論,0人參與

請輸入評論內容...

請輸入評論/評論長度6~500個字

您提交的評論過于頻繁,請輸入驗證碼繼續

暫無評論

暫無評論

文章糾錯
x
*文字標題:
*糾錯內容:
聯系郵箱:
*驗 證 碼:

粵公網安備 44030502002758號

电竞投注竞彩app